| 1 |
29283173 | CYP3A4 inducer and inhibitor strongly affect the pharmacokinetics of triptolide and its derivative in rats. | 2018 Aug |
1 |
| 2 |
23589366 | Time-dependent interaction of ritonavir in chronic use: the power balance between inhibition and induction of P-glycoprotein and cytochrome P450 3A. | 2013 Jun |
4 |
| 3 |
23873286 | Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model. | 2013 Oct |
1 |
| 4 |
22308076 | Effect of grapefruit juice and ritonavir on pharmacokinetics of lopinavir in Wistar rats. | 2012 Oct |
2 |
| 5 |
18520056 | Long-term pharmacokinetic efficacy and safety of low-dose ritonavir as a booster and atazanavir pharmaceutical formulation based on solid dispersion system in rats. | 2008 Jun |
4 |
| 6 |
17409512 | Pharmaceutical approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion system. | 2007 Apr |
2 |
| 7 |
15635177 | Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats. | 2005 Jan |
5 |
| 8 |
14985144 | Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats. | 2004 Feb |
5 |
| 9 |
12604693 | Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. | 2003 Mar |
1 |